Immunotherapy in advanced gastric cancer, is it the future?. (January 2019)

• Record Type: Journal Article
• Authors: Coutzac, C.; Pernot, S.; Chaput, N.; Zaanan, A.
• Is Part Of: Critical reviews in oncology/hematology. Volume 133(2019)
• Page Start: 25
• Page End: 32
• Publication Date: 2019-01
• Subjects: Advanced gastric cancer -- Immunotherapy -- CTLA-4 -- PD-1 -- PD-L1; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2018.10.007
• Languages: English
• ISSNs: 1040-8428

Abstract

Abstract: The prognosis of advanced gastric cancer remains extremely poor despite the use of standard therapies such as chemotherapy and biological agents. Blocking immune checkpoint especially programmed cell death-1 (PD-1) and its ligand (PD-L1 or B7-H1), has proven efficacy in several solid cancers, and seems to become a potential option in gastric cancer treatment. This review will focus on data describing the immune microenvironment of gastric tumors on which blocking PD-1/PD-L1 axis may have an anti-tumor efficacy. Then, the encouraging results of clinical trials evaluating anti-PD-1/PD-L1-based therapeutic strategy in first or later-line settings will be discuss. Finally, clinical outcomes according to PD-L1 expression, mismatch repair phenotype and other potential predictive biomarkers of anti-tumor response will be described. Altogether, immunotherapy seems promising in advanced gastric cancer in monotherapy or in combining strategies probably for a specific subgroup of patients who need to be better identified.